GURUFOCUS.COM » STOCK LIST » Healthcare » Healthcare Providers & Services » NetraMark Holdings Inc (XCNQ:AIAI) » Definitions » Debt-to-EBITDA

NetraMark Holdings (XCNQ:AIAI) Debt-to-EBITDA : 0.00 (As of Mar. 2024)


View and export this data going back to 2021. Start your Free Trial

What is NetraMark Holdings Debt-to-EBITDA?

Debt-to-EBITDA measures a company's ability to pay off its debt.

NetraMark Holdings's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2024 was C$0.00 Mil. NetraMark Holdings's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2024 was C$0.00 Mil. NetraMark Holdings's annualized EBITDA for the quarter that ended in Mar. 2024 was C$-2.86 Mil. NetraMark Holdings's annualized Debt-to-EBITDA for the quarter that ended in Mar. 2024 was 0.00.

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.

The historical rank and industry rank for NetraMark Holdings's Debt-to-EBITDA or its related term are showing as below:

XCNQ:AIAI's Debt-to-EBITDA is not ranked *
in the Healthcare Providers & Services industry.
Industry Median: 2.55
* Ranked among companies with meaningful Debt-to-EBITDA only.

NetraMark Holdings Debt-to-EBITDA Historical Data

The historical data trend for NetraMark Holdings's Debt-to-EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

NetraMark Holdings Debt-to-EBITDA Chart

NetraMark Holdings Annual Data
Trend Sep20 Sep21 Sep22 Sep23
Debt-to-EBITDA
- - - -

NetraMark Holdings Quarterly Data
Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Sep23 Dec23 Mar24
Debt-to-EBITDA Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - N/A - -

Competitive Comparison of NetraMark Holdings's Debt-to-EBITDA

For the Health Information Services subindustry, NetraMark Holdings's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


NetraMark Holdings's Debt-to-EBITDA Distribution in the Healthcare Providers & Services Industry

For the Healthcare Providers & Services industry and Healthcare sector, NetraMark Holdings's Debt-to-EBITDA distribution charts can be found below:

* The bar in red indicates where NetraMark Holdings's Debt-to-EBITDA falls into.



NetraMark Holdings Debt-to-EBITDA Calculation

Debt-to-EBITDA measures a company's ability to pay off its debt.

NetraMark Holdings's Debt-to-EBITDA for the fiscal year that ended in Sep. 2023 is calculated as

Debt-to-EBITDA=Total Debt / EBITDA
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / EBITDA
=(0 + 0) / -5.358
=0.00

NetraMark Holdings's annualized Debt-to-EBITDA for the quarter that ended in Mar. 2024 is calculated as

Debt-to-EBITDA=Total Debt / EBITDA
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / EBITDA
=(0 + 0) / -2.864
=0.00

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data, the EBITDA data used here is four times the quarterly (Mar. 2024) EBITDA data.


NetraMark Holdings  (XCNQ:AIAI) Debt-to-EBITDA Explanation

In the calculation of Debt-to-EBITDA, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by EBITDA. In some calculations, Total Liabilities is used to for calculation.


Be Aware

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.

According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.


NetraMark Holdings Debt-to-EBITDA Related Terms

Thank you for viewing the detailed overview of NetraMark Holdings's Debt-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.


NetraMark Holdings (XCNQ:AIAI) Business Description

Traded in Other Exchanges
Address
1655 Dupont Street, Suite 101, Toronto, ON, CAN, M6P 3T1
NetraMark Holdings Inc is focused on the application of a totally unique Artificial Intelligence (AI) / Machine Learning (ML) solution targeted at the pharmaceutical industry in order to de-risk clinical trials. NetraMark has a proprietary technology that is capable of cutting through the combinatorial complexity that comes with dealing with heterogeneous patient populations to extract precisely defined personas of patients with respect to placebo and drug response, in addition to tolerability and adverse events. By using the client's own contemporaneous data, and having the capacity to learn from small data, the NetraAI tech extracts these personas to equip pharmaceutical companies with strategies to optimize their next trials for success.
Executives
Andrew Parks Director

NetraMark Holdings (XCNQ:AIAI) Headlines

No Headlines